CUE — Cue Biopharma Share News
0.000.00%
Last trade - 00:00- $102.72m
- $86.34m
- $27.47m
Brief: Cue Biopharma Announces Strategic Organizational Transition
Brief: Cue Biopharma Inc Enters Second Amendment To Loan Agreement With Svb
U.S. RESEARCH ROUNDUP-Coca-Cola Co, Estée Lauder, Quanta Services
Brief: Cue Biopharma Announces Proposed Public Offering
U.S. RESEARCH ROUNDUP-Alexander & Baldwin, Instructure Holdings, RPM International
Brief: Cue Biopharma To Slash 25% Workforce
Brief: Cue Biopharma Presents Updated Data from Phase 1 Trial of CUE-101 in Recurrent/Metastatic HPV+ Head and Neck Cancer at the 2024 ASCO Annual Meeting
Cue Biopharma Inc reports results for the quarter ended in January - Earnings Summary
Cue Biopharma Inc expected to post a loss of 28 cents a share - Earnings Preview
U.S. RESEARCH ROUNDUP-CME Group, Danimer Scientific, Intercontinental Exchange
Cue Biopharma Inc reports results for the quarter ended in December - Earnings Summary
Cue Biopharma Inc expected to post a loss of 28 cents a share - Earnings Preview
U.S. RESEARCH ROUNDUP- Pioneer Natural Resources,Oxford Industries, Nutrien
Cue Biopharma Inc reports results for the quarter ended in June - Earnings Summary
Brief: Cue Biopharma, Inc. Q2 collaboration revenue USD 1.382 million
Cue Biopharma Inc expected to post a loss of 30 cents a share - Earnings Preview
Brief: Cue Biopharma Presents Positive Data Update From Ongoing Phase 1 Trials Of Cue-101 For Recurrent/Metastatic Hpv+ Head And Neck Squamous Cell Carcinoma At The 2023 American Society Of Clinical Oncology Annual Meeting
Cue Biopharma Inc reports results for the quarter ended in March - Earnings Summary
Brief: Cue Biopharma Inc Files For Mixed Shelf Offering Of Up To $300 Mln